Please ensure Javascript is enabled for purposes of website accessibility

Why GenMark Diagnostics, Inc. Is Soaring Today

By Brian Feroldi – Sep 16, 2016 at 12:58PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares jump in response to an analyst upgrade.

Image source: Getty Images.

What happened

Shares of GenMark Diagnostics (GNMK), a molecular-diagnostics company, are on the move today. The markets are bidding the company's stock up more than 18% as of 11:15 a.m. EDT in response to GenMark receiving a upgrade from an analyst.

So what

GenMark's investors can thank Doug Schenkel, an analyst at Cowen, for the company's positive price action. 

Schenkel said that his firm had previously downgraded GenMark due to delays related to regulatory submissions of its next-generation testing product, the ePlex system. However, those concerns have since been alleviated, giving Schenkel conviction that the company is on target to launch the ePlex system in the U.S. in early 2017. As a result, Schenkel raised his rating on the stock to "outperform" and set a price target of $17.

That's quite a bullish call. Yesterday this stock closed at $8.82, so the new price target calls for an almost doubling of the share price.

The upbeat outlook has certainly caught the market's attention, which is why shares are up so much today.

Now what

GenMark's ePlex system looks like it could be the real deal. The company is saying that the new system will be very easy to use and provide far faster testing results than other systems, which is an attractive combination that could catch the attention of many healthcare providers.

Of course, the company will certainly face its fair share of competition if it can eventually bring the ePlex system to market. One name for investors to keep an eye on is Cepheid (NASDAQ: CPHD), another molecular diagnostics company, which was recently acquired by Danaher (DHR -1.47%) in a $4 billion deal. Danaher already has a big diagnostic business with a worldwide network and reputation for excellence, so it's possible that Cepheid's market share could continue to grow in response to the buyout. After all, Danaher has a long history of acquiring other businesses and then making them even more competitive, so this is a company that GenMark's investors need to keep tabs on. 

Still, the ePlex system looks like it offers enough advantages to hold its own once it comes to market, so GenMark's revenue could be poised to soar in the years ahead. However, since this company is still firmly in the red, and regulatory success for the ePlex is far from guaranteed, I'd advise potential investors to proceed with caution.

Brian Feroldi has no position in any stocks mentioned. Like this article? Follow him on Twitter where he goes by the handle @Longtermmindset or connect with him on LinkedIn to see more articles like this.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GenMark Diagnostics, Inc. Stock Quote
GenMark Diagnostics, Inc.
GNMK
Danaher Corporation Stock Quote
Danaher Corporation
DHR
$258.29 (-1.47%) $-3.86

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.